NCT01159665View on ClinicalTrials.gov

The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

January 31, 2011

Conditions
Vitrectomy
Interventions
DRUG

ocriplasmin

125µg ocriplasmin intravitreal injection

DRUG

ocriplasmin

125µg ocriplasmin intravitreal injection

DRUG

ocriplasmin

125µg ocriplasmin intravitreal injection

DRUG

ocriplasmin

125µg ocriplasmin intravitreal injection

DRUG

ocriplasmin

125µg ocriplasmin intravitreal injection

Trial Locations (1)

B-3000

University Hospital Leuven, Leuven

Sponsors

Lead Sponsor

ThromboGenics
All Listed Sponsors
lead

ThromboGenics

INDUSTRY